



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Global Anthrax Partnering 2012 to 2018

Global Anthrax Partnering 2012 to 2018

Publication ID:

CPA0918115

Publication Date:

September 01, 2018

Pages:

150

Publisher:

Current Partnering

Region:

Global [1]

\$1,995.00

Publication License Type *

Single User License (PDF), \$1,995.00

Site License (PDF), \$4,995.00

Global License (PDF), \$7,995.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Provides understanding and access to the anthrax partnering deals and agreements entered into by

the world's leading healthcare companies.

Description

The Global Anthrax Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

- Trends in partnering deals
- Top deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2012, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2012. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2012 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2012 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Benefits

Global Anthrax Partnering Terms and Agreements since 2012 report provides the reader with the following key benefits:

- In-depth understanding of deal trends since 2012
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to multiple deals entered into by the world's biopharma companies since 2012
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents:

Executive Summary

Chapter 1 - Therapypartnering trends in numbers

Partnering in numbers - by year

Partnering in numbers - most active

Partnering in numbers - by industry sector

Partnering in numbers - by deal type

Partnering in numbers - by technology type

Partnering in numbers - by stage of development

Chapter 2 - Most active dealmakers

Chapter 3 - Partnering deals directory

Partnering deals directory - by company A-Z

Partnering deals directory - by deal value

Partnering deals directory - by industry sector

Partnering deals directory - by deal type

Partnering deals directory - by stage of development

Partnering deals directory - by technology area

Chapter 4 - Partnering deals with a contract document

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

TABLE OF FIGURES

Figure 1: Partnering frequency by year

Figure 2: Partnering most active

Figure 3: Partnering by industry sector

Figure 4: Partnering by deal type

Figure 5: Partnering by technology area

Figure 6: Partnering by stage of development

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/current-partnering/global-anthrax-partnering-2012-2018>

Links

[1] <https://www.drugpipeline.net/region/global>